Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025Diabetes Obesity and MetabolismOpen Access

Biomarkers for cardiovascular–kidney metabolic syndrome: Clinical utility in diagnosis, screening, and treatment

View Full Paper
Ask AI
Bookmark
Share

Authors

KYKevin YauDCDavid Z.I. CherneyAOAyodele Odutayo

Discussion

Loading...

Member takes

Overview

This review highlights the role of biomarkers like albuminuria and NT-proBNP in screening and managing cardiovascular disease and chronic kidney disease.

Key Points

  • Biomarkers play a crucial role in managing cardiovascular disease and chronic kidney disease by aiding diagnosis and treatment decisions.
  • Screening for albuminuria significantly helps in risk assessment, especially in populations with diabetes or hypertension.
  • N-terminal B-type natriuretic peptide is vital for early diagnosis of heart failure and may inform therapeutic strategies for chronic kidney disease.
  • High-sensitivity troponin provides insightful data in cardiac evaluations, although its integration in routine care settings remains a work in progress.

Cite This Study

Yau et al. (2025) studied this question.

synapsesocial.com/papers/68c23887b210217d64777c65https://doi.org/10.1111/dom.70044
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched one closely related paper. Consider it for comparative context:

  1. 1Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes2023 · 41 citations